Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Not yet recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 12Gastrointestinal 8Tumor-Agnostic 3Head & Neck 3Breast 3Gynecologic 2CNS 2Sarcoma 1Other solid neoplasm 1Endocrine 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × anlotinib × Tumor-Agnostic × Clear all
NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Henan Cancer Hospital

Phase 2 Completed
42 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01878448 2019-05-22

ALTN/STS

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
166 enrolled
Tumor-Agnostic

Neoplasms

NCT01874873 2019-05-21

ALTN/MTC

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
58 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡